- Home
- LVTX vs NRSN Comparison
LVTX vs NRSN Comparison
Compare LVTX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- NRSN
- Stock Information
- Founded
- LVTX 2016
- NRSN 2017
- Country
- LVTX Netherlands
- NRSN Israel
- Employees
- LVTX N/A
- NRSN N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- NRSN Health Care
- Exchange
- LVTX Nasdaq
- NRSN Nasdaq
- Market Cap
- LVTX 30.0M
- NRSN 26.0M
- IPO Year
- LVTX 2021
- NRSN 2021
- Fundamental
- Price
- LVTX $1.25
- NRSN $1.04
- Analyst Decision
- LVTX Hold
- NRSN Hold
- Analyst Count
- LVTX 3
- NRSN 1
- Target Price
- LVTX $3.17
- NRSN N/A
- AVG Volume (30 Days)
- LVTX 48.1K
- NRSN 99.3K
- Earning Date
- LVTX 05-20-2025
- NRSN 06-23-2025
- Dividend Yield
- LVTX N/A
- NRSN N/A
- EPS Growth
- LVTX N/A
- NRSN N/A
- EPS
- LVTX N/A
- NRSN N/A
- Revenue
- LVTX $11,982,000.00
- NRSN N/A
- Revenue This Year
- LVTX N/A
- NRSN N/A
- Revenue Next Year
- LVTX N/A
- NRSN N/A
- P/E Ratio
- LVTX N/A
- NRSN N/A
- Revenue Growth
- LVTX 77.01
- NRSN N/A
- 52 Week Low
- LVTX $0.85
- NRSN $0.51
- 52 Week High
- LVTX $3.20
- NRSN $1.50
- Technical
- Relative Strength Index (RSI)
- LVTX 49.77
- NRSN 53.20
- Support Level
- LVTX $1.17
- NRSN $0.93
- Resistance Level
- LVTX $1.37
- NRSN $1.08
- Average True Range (ATR)
- LVTX 0.08
- NRSN 0.06
- MACD
- LVTX -0.01
- NRSN 0.01
- Stochastic Oscillator
- LVTX 29.85
- NRSN 71.12
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.